“…The subjects included six healthy volunteers (6 samples: H-1, H-2, H-3, H-4, H-5 and H-6) (22), two volunteers with systemic lupus erythematosus (SLE) (including 6 total samples pretreatment, during treatment and after treatment, namely, S1-1, S1-2, S1-3, S2-1, S2-2 and S2-3) (23), three volunteers with breast cancer (including 9 total samples pretreatment, during treatment and after treatment, namely, B3-1, B2-1, B1-1, B3-2, B2-2, B1-2, B3-3, B2-3, and B1-3), two volunteers with a high titer of HBsAb (2 samples: HBsAb-1, HBsAb-2) (24) and three volunteers with samples before and after immunization with the HBV vaccine (6 IgM samples (V1-BM, V1-AM, V2-BM, V2-AM, V3-BM, V3-AM) and 6 IgG samples (V1-BG, V1-AG, V2-BG, V2-AG, V3-BG, and V3-AG)) (25). The peripheral blood samples were obtained from the Affiliated Hospital of Zunyi Medical University.…”